Yunxiang Xu

Cooley advised Innogen Pharmaceutical on its HK$682.87 million initial public offering (IPO).

Cooley advised Nanjing Leads Biolabs Co. (Leads Biolabs), a clinical-stage biotechnology company that discovers, develops and commercializes new therapies in oncology, autoimmune and other severe diseases, on its HK$1.29 billion initial public offering (IPO).

Cooley advised the underwriters of Duality Biologics (DualityBio), a clinical-stage biotech company focused on the discovery and development of next-generation antibody-drug conjugate therapeutics for patients with cancer and autoimmune diseases, in connection with its HK$1.64 billion global initial public offering (IPO).

Cooley advised ImmuneOnco Biopharmaceuticals, a clinical-stage biotechnology company dedicated to the development of immuno-oncology therapies, on its HK$319 million initial public offering.